{"name":"CareCanon drug label registry","description":"A source-linked registry of the FDA prescribing labels in CareCanon’s current collection.","canonical":"https://carecanon.com/data","methodology":"https://carecanon.com/methodology","sourcePublisher":"DailyMed, U.S. National Library of Medicine","generatedAt":"2026-08-29T19:54:32.487Z","recordCount":5,"scope":"Five originator GLP-1 labels currently tracked by CareCanon; not every FDA drug label.","fields":["recordId","brand","ingredient","slug","maker","indication","setid","labelTitle","labelPublished","retrievedAt","sourceUrl","revisionCount","hasTitrationTable","marketedStrengthsMg"],"records":[{"recordId":"ee06186f-2aa3-4990-a760-757579d8f77b","brand":"WEGOVY","ingredient":"semaglutide","slug":"wegovy","maker":"Novo Nordisk","indication":"chronic weight management","setid":"ee06186f-2aa3-4990-a760-757579d8f77b","labelTitle":"WEGOVY (SEMAGLUTIDE) INJECTION, SOLUTION WEGOVY (SEMAGLUTIDE) TABLET [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP]","labelPublished":"Jun 30, 2026","retrievedAt":"2026-08-29T19:54:27.703Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","revisionCount":5,"hasTitrationTable":true,"marketedStrengthsMg":[0.25,0.5,1,1.5,1.7,2.4,4,7.2,9,25]},{"recordId":"adec4fd2-6858-4c99-91d4-531f5f2a2d79","brand":"OZEMPIC","ingredient":"semaglutide","slug":"ozempic","maker":"Novo Nordisk","indication":"type 2 diabetes","setid":"adec4fd2-6858-4c99-91d4-531f5f2a2d79","labelTitle":"OZEMPIC (SEMAGLUTIDE) INJECTION, SOLUTION [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP]","labelPublished":"Jun 10, 2026","retrievedAt":"2026-08-29T19:54:28.918Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","revisionCount":1,"hasTitrationTable":false,"marketedStrengthsMg":[0.25,0.5,1,2]},{"recordId":"27f15fac-7d98-4114-a2ec-92494a91da98","brand":"RYBELSUS","ingredient":"semaglutide","slug":"rybelsus","maker":"Novo Nordisk","indication":"type 2 diabetes (oral)","setid":"27f15fac-7d98-4114-a2ec-92494a91da98","labelTitle":"OZEMPIC (ORAL SEMAGLUTIDE) TABLET RYBELSUS (ORAL SEMAGLUTIDE) TABLET [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP]","labelPublished":"Aug 19, 2026","retrievedAt":"2026-08-29T19:54:30.107Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98","revisionCount":6,"hasTitrationTable":false,"marketedStrengthsMg":[3,7,14]},{"recordId":"487cd7e7-434c-4925-99fa-aa80b1cc776b","brand":"ZEPBOUND","ingredient":"tirzepatide","slug":"zepbound","maker":"Eli Lilly","indication":"chronic weight management","setid":"487cd7e7-434c-4925-99fa-aa80b1cc776b","labelTitle":"ZEPBOUND (TIRZEPATIDE) INJECTION, SOLUTION ZEPBOUND (TIRZEPATIDE) INJECTION, SOLUTION ZEPBOUND KWIKPEN (TIRZEPATIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY]","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:31.296Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b","revisionCount":3,"hasTitrationTable":false,"marketedStrengthsMg":[2.5,5,7.5,10,12.5,15]},{"recordId":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0","brand":"MOUNJARO","ingredient":"tirzepatide","slug":"mounjaro","maker":"Eli Lilly","indication":"type 2 diabetes","setid":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0","labelTitle":"MOUNJARO (TIRZEPATIDE) INJECTION, SOLUTION MOUNJARO KWIKPEN (TIRZEPATIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY]","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:32.487Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","revisionCount":5,"hasTitrationTable":false,"marketedStrengthsMg":[2.5,5,7.5,10,12.5,15]}]}